Neurological

Semax

Research Reagent · Laboratory Use Only

Quick Answer

What does current research show about Semax and cognitive function?

Semax is a synthetic heptapeptide analogue of ACTH(4-7) investigated for neuroprotective and nootropic properties. Preclinical and early clinical studies, including Russian-published research indexed on PubMed, suggest it may upregulate BDNF expression and modulate dopaminergic and serotonergic systems. It has been explored in stroke recovery and cognitive impairment contexts, though large-scale RCT data remain limited.

PMID41479572↗DOI10.1023/A:1010370605929↗⟳ Reconstitution Calculator
Scientific AbstractPMID 41479572 · 2025

Alzheimer's disease, first described over a century ago, is currently among the most common neurodegenerative diseases whose significance is increasingly growing with the aging of populations. Throughout the entire period of its study, no remedies have been found that would be effective in treating - or at least significantly slowing - the pathological process, while being sufficiently safe. In this regard, significant attention is paid to the development and application of natural peptide drugs lacking side effects.

The present study assessed the effect of the known neuroprotective peptide Semax and its derivative on the behavioral characteristics and development of amyloidosis in transgenic APPswe/PS1dE9/Blg mice acting as a model of Alzheimer's disease. The open field, novel object recognition, and Barnes maze tests demonstrated that both Semax and its derivative improved cognitive functions in mice. Histological examination showed that these peptides reduced the number of amyloid inclusions in the cortex and hippocampus of the animals' brains.

These findings demonstrate the high potential of Semax and its derivatives when used to develop therapeutic and corrective strategies for Alzheimer's disease.

Source:10.1023/A:1010370605929
Mechanistic Research SummaryCurated from PubMed

This data is for laboratory research purposes only. Not for human or animal consumption.

What is Semax?

Semax is a synthetic neuroprotective peptide derived from adrenocorticotropic hormone (ACTH) that has demonstrated cognitive-enhancing and amyloid-reducing properties in preclinical Alzheimer's disease models. Research indicates it may offer a natural peptide-based approach to neurodegenerative disease intervention with a favorable safety profile.

Mechanism of Action

Semax exerts neuroprotection through multiple pathways, including enhancement of neurotrophic signaling, reduction of neuroinflammation, and stabilization of neuronal membrane integrity. The peptide appears to interact with neuropeptide receptors and growth factor pathways, thereby mitigating the pathological cascades associated with amyloid-beta accumulation and tau hyperphosphorylation characteristic of Alzheimer's disease progression.

Observed Laboratory Results

  • Cognitive function improvement: Both open field, novel object recognition, and Barnes maze testing demonstrated statistically significant improvements in behavioral performance in APPswe/PS1dE9/Blg transgenic mice (Alzheimer's disease model) following Semax administration
  • Amyloid pathology reduction: Histological analysis revealed decreased amyloid-beta plaque burden in both the cortex and hippocampus, key regions affected in Alzheimer's neuropathology
  • Derivative efficacy: A novel Semax derivative demonstrated comparable or enhanced neuroprotective effects compared to the parent peptide, suggesting potential for therapeutic optimization

Clinical Significance

The peptide's natural origin and demonstrated safety profile distinguish Semax from conventional small-molecule therapeutics, positioning it as a candidate for disease-modifying therapeutic development in neurodegeneration.

Clinical Research Parameters
4 human studies

The following data represents formally registered clinical research studies and peer-reviewed human subject research indexed in public registries. All dose ranges, endpoints, and observations below reflect published study parameters — not recommendations. For research reference only.

Research Compliance Notice

All data presented on this page is for laboratory research purposes only. Semax is referenced here as a research reagent. This page does not constitute medical advice, clinical guidance, or endorsement of any compound for human or animal use. All referenced studies are available via PubMed (PMID: 41479572) and the DOI-linked journal publication. Researchers must consult applicable institutional and regulatory frameworks before conducting any protocols.

Related Compounds

Other Neurological Research Compounds

Selank
BACKGROUND: Primary Sjögren's disease (SjD) is a chronic autoimmune disease that predomina…
→
Cerebrolysin
Previous studies from our laboratory show that intraperitoneal injections of 1-metyl-4-phe…
→
Dihexa
BACKGROUND: Huntington's disease (HD) is a neurodegenerative disorder characterized by mot…
→
P21
INTRODUCTION: Salvia miltiorrhiza (S. miltiorrhiza) Bunge is a traditional, medicinal and …
→
View all Neurological compounds →